Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Ensysce Biosciences submitted a Phase 2a protocol to the UK MHRA for CY200 in CRPS Type 1, a randomized, placebo-controlled proof-of-concept study planned in the UK.Material DetailsContext by AI AnalystThis is an early clinical milestone signaling execution on a newly acquired neuroplastigen asset…
~ Submission to the UK MHRA for review marks critical step towards initiating a Phase 2 Study with CY200 ~SAN DIEGO, CA / / September 24, 2026 / Ensysce Biosciences, Inc. NASDAQ:ENSC ("Ensysce" or the "Company"), a clinical-stage biotechnology company developing novel neuroplastogen…
ENSC - Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA